In pharma and biotech, digital systems rarely stay the same after they go live. Workflows change, users increase, integrations are added, suppliers release updates, and the system becomes part of a larger operational environment. The real challenge is that oversight does not always evolve at the same pace. A system may still be validated, documented,
SaaS and cloud validation is different because the regulated company no longer controls the full technical stack, but it still owns intended use, oversight, data integrity, access, and compliance. That is where many teams misunderstand the real validation challenge. When a system is vendor-hosted, the validation work does not go away. It shifts. Instead of
For a growing biotech company, implementing the first major digital system is an important milestone. Paper records, spreadsheets, shared drives, and disconnected tools that worked during early growth may no longer support increasing operational complexity, regulatory expectations, or future scale. The natural response is often to start evaluating software. But selecting an eQMS, LIMS, LMS,
How Assurea validated a U.S. deployment of Veeva Vault Quality and established a reusable validation framework for future global site rollouts. Project Overview When a global Contract Development and Manufacturing Organization (CDMO) selected Veeva Vault Quality to standardize its quality management processes, the first deployment was planned for a U.S. manufacturing site located on the
Many life sciences organizations commonly ask this question when implementing a SaaS platform: “If the vendor already validated the system, what do we still need to do?” The answer is straightforward. The vendor is responsible for the platform it develops, operates, and maintains. The regulated company remains responsible for how that platform is configured, governed,
In today’s digital biotech environment, labs and manufacturing sites rely on a complex network of interconnected systems: LIMS, QMS, MES, ERP, CDS, eBMRs, data historians, and analytics platforms. While each system may be validated independently, the movement of data between them is where the highest risk now lives. Regulators increasingly expect organizations to demonstrate end-to-end
Background: A Late-Stage Biopharma Preparing for EU Commercialization A mid-sized U.S.-based biopharmaceutical company was preparing to commercialize its first biologic product in the European Union. As part of its global expansion strategy, the company initiated a technology transfer from its U.S. clinical manufacturing facility to a commercial EU site (located in Ireland). While the company
Client: A Biotech CompanyIndustry: Life Sciences / Pharmaceutical ManufacturingSize: 150–200 employeesEngagement Type: Full-service contract staffing partnershipPartner: Assurea Background A rapidly growing biotech company specializing in cell and gene therapy recently secured Series C funding to expand its manufacturing capacity. The organization planned to establish a new biomanufacturing site in New Jersey, aimed at scaling production
The FDA has finalized its Computer Software Assurance for Production and Quality System Software guidance — a long-awaited update that signals the end of “business as usual” for software validation in regulated industries. For decades, Computerized System Validation (CSV) has been the framework life sciences companies relied on. While it provided structure, CSV often created
Background A mid-sized U.S.-based medical device manufacturer was preparing to initiate a clinical trial for a new Class II device. The company needed additional Clinical Research Associate (CRA) support to oversee trial sites, ensure protocol compliance, and meet regulatory expectations. With limited internal bandwidth and a fast-approaching study start date, the client turned to Assurea’s